PinnyPeptide

Cartalax vs Vesilute

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Cartalax

Bioregulators

Khavinson short peptide bioregulator targeting chondrocytes and connective tissue.

Peptide B

Vesilute

Bioregulators

Khavinson short peptide bioregulator targeting urinary bladder epithelium.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Cartalax effects

  • Reported support of chondrocyte function and cartilage matrix synthesis
  • Improvements in joint pain and mobility (Russian observational)
  • Possible slowing of age-related cartilage degradation
  • Recovery support after cartilage injury
  • Modulation of connective-tissue gene expression

Vesilute effects

  • Reported improvement in chronic cystitis symptoms
  • Possible reduction in overactive bladder symptoms
  • Anti-inflammatory effects in bladder tissue
  • Support of bladder epithelial integrity
  • Modulation of bladder gene expression

Cartalax side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation

Vesilute side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Not a substitute for proper urological evaluation

Cartalax dosing ranges

Joint / cartilage support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Vesilute dosing ranges

Bladder function support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Full Cartalax guide → Full Vesilute guide →

Cartalax vs Vesilute — common questions

What is the difference between Cartalax and Vesilute?

Cartalax: Khavinson short peptide bioregulator targeting chondrocytes and connective tissue. Typical dose 1,000-5,000 mcg. Vesilute: Khavinson short peptide bioregulator targeting urinary bladder epithelium. Typical dose 1,000-5,000 mcg. Both fall under the Bioregulators category.

Can you stack Cartalax and Vesilute?

Stacking Cartalax with Vesilute is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Cartalax or Vesilute?

Cartalax is typically dosed: Once daily (SubQ) or sublingual for Joint / cartilage support. Vesilute is typically dosed: Once daily (SubQ) or sublingual for Bladder function support.

Are Cartalax and Vesilute FDA approved?

Cartalax: Not FDA approved. Vesilute: Not FDA approved.

Related peptide comparisons

bronchogen vs cartalaxcardiogen vs cartalaxcartalax vs cortagencartalax vs crystagencartalax vs ovagencartalax vs pancragen

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free